Tuesday 13 October 2026
Export ALT’s income statement to Excel — free account
Altimmune, Inc.
Altimmune, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41,000.00, up 105.0% from fiscal 2024. In the quarter to June 2026, revenue grew 520.0%, EPS grew 55.6%, free cash flow fell 25.3% and total debt rose 142.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.47
0.09
−3.52%
Follow ALT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 6,914.26 | 16,855.29 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (16.35) | (28.34) | |
P/B ratio |
— | — | 1.41 | 1.82 | |
Price to Tangible BV |
— | — | 1.50 | 1.95 | |
EV/Sales |
— | — | 1,717.80 | 7,045.34 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (1.17) | (2.12) | |
EV/FCF |
— | — | (1.17) | (2.12) | |
Quick Ratio |
26.37 | 29.43 | 18.35 | 16.83 | |
Current Ratio |
26.78 | 29.56 | 18.55 | 17.18 | |
Net Debt/EBITDA |
10.82 | 11.94 | 8.09 | 9.39 | |
Debt/Assets |
6.59% | 10.28% | 12.25% | 6.61% | |
Debt/Equity |
0.07 | 0.12 | 0.15 | 0.08 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.06 | 0.93 | 0.71 | 0.63 | |
Capex/Depreciation |
0.04 | 0.03 | 0.00 | 0.00 | |
Interest Coverage |
(23.91) | (22.70) | (32.98) | (42.14) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 59,383.87% | 299,200.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 33,903.23% | 118,080.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 15,938.71% | 71,080.00% | |
Graham Net Nets |
— | — | 0.70 | 0.55 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (27.98%) | (28.38%) | |
Free Cash Flow Yield |
— | — | (21.30%) | (19.74%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.13) | (0.17) | (0.22) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.17) | (0.22) | (0.13) | |
Cash per Share |
1.76 | 2.66 | 3.10 | 2.36 | |
Shareholders Equity per Share |
2.56 | 2.28 | 2.55 | 2.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.56 | 2.28 | 2.55 | 2.08 | |
Free Cash Flow |
(24.25) | (20.96) | (19.45) | (11.90) | |
Working Capital |
322.31 | 323.35 | 263.20 | 204.01 | |
Capital Expenditures |
(0.03) | (0.02) | 0.00 | 0.00 | |
Net Current Asset Value |
281.81 | 283.03 | 223.16 | 183.77 | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.03 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.11 | 2.06 | 2.43 | 2.37 | |
Average Payables |
1.06 | 1.30 | 1.46 | 2.97 | |
Average Assets |
358.78 | 246.45 | 209.62 | 183.16 | |
Average Common Equity |
317.79 | 213.07 | 174.20 | 159.49 |
Columns are period end dates